

## Notice Concerning Revision of the Full-Year Financial Guidance for Fiscal Year Ending March 31, 2023 (FY2022)

TOKYO, JAPAN – February 9, 2023 – Terumo Corporation (TSE: 4543) today announced that it revised the full-year financial guidance for the year ending March 31, 2023 (FY2022) which was announced on May 12, 2022.

### 1. Full-Year Financial Guidance for FY2022 (From April 1, 2022 to March 31, 2023)

	Revenue (Million yen)	Adjusted operating profit (Million yen)	Operating profit (Million yen)	Profit attributable to owners of parent (Million yen)	Basic earnings per share (Yen)
Previous guidance (A)	775,000	151,000	132,000	100,000	133.88
Revised guidance (B)	815,000	143,000	122,000	91,500	121.90
Difference (B)-(A)	40,000	△ 8,000	△ 10,000	△ 8,500	—
Rate of change	5.2%	△ 5.3%	△ 7.6%	△ 8.5%	—
(Reference) Results for FY2021	703,303	134,441	115,960	88,813	117.45

### 2. Reasons of the Revision

Terumo anticipates consolidated revenue of 815 billion yen, an increase of 40 billion yen from the previous forecast. This increase is mainly due to the greater depreciation of the yen than originally anticipated at the beginning of this fiscal year.

Terumo anticipates lower than previously forecasted adjusted operating profit and operating profit in light of the deteriorating macroeconomic environment, and the current status of new business development.

Profit attributable to owners of the parent is anticipated to be 91.5 billion yen, a decrease of 8.5 billion yen from the previous forecast due to a decrease in operating profit.

### About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare

ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

### **Disclaimer**

Among the information that Terumo discloses, the forward-looking statements including financial projections contain potential risks and uncertainty since these are made by Terumo based on limited information available at the moment of disclosure. Accordingly, it should be noted that actual results might differ from those statements due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.